South Africa

AstraZeneca is a global innovation driven biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.

Science can change our vision of the world and how we deal with the diseases that affect us. The future of treatment for many of today’s diseases lies in uncovering disease mechanisms that are newly emerging or are still to be discovered. Science challenges us to push the limits of what is possible. This is why we put science at the centre of everything we do.

At AstraZeneca South Africa every one of our 180 employees makes a difference to patient lives every day. We are inspired by the things that seem impossible and stimulate continued creativity throughout our organisation, maintaining a culture in which our people feel valued for their ideas and contributions. Ideas that can make a difference in all aspects of our business and to healthcare in South Africa.

Our Johannesburg office serves as a hub of communication between our office-based staff and more than half the company's employees that are directly involved in the promotion of our medicines to healthcare professionals throughout the country.

AstraZeneca South Africa has been working to deliver the best value to patients for over 17 years. Our vision is to transform the lives of patients, ensuring South Africans have access to our innovative medicines.

Contact Details

Building 2
Northdowns Office Park
17 Georgian Crescent West
Johannesburg – South Africa
Tel:+27 (0) 11 797 6000
Fax: +27 (0) 86 640 1463


Our senior management team

Rodney Gillespie                     Country President South Africa

Dr Donald Ngwira                     Medical and Regulatory Affairs Director

Aykut Bolat                              Interim Chief Financial Officer SA

Pumza Seokane                       Human Resources Director SA & SSA

Selwyn Solomon                      Commercial Excellence Director

Ursula Du Preez                       Business Unit Director Cardiovascular and Metabolic Disease 

Jaki Fagan                               Business Unit Director Oncology 

Dr Tamu Dube                          Business Unit Director Respiratory

Ruth Field                                Market Access Director

Reshma Singh                         Compliance Senior Manager


Research & Development

AstraZeneca South Africa has proven its willingness to play a significant role in international R&D through a strong investment in clinical studies, across therapeutic areas, with added value for local doctors and patients.

We have had significant involvement in the rich pipeline of candidate drugs emerging from R&D sites. High quality work with specialists and primary care physicians throughout the country over the past years has resulted in a steady increase of trial work being awarded to the Clinical Research Department in South Africa, which attained key country status in 2000.

Our focus in on adding value, not only to our global company’s research and development programme, but also to the society within which we operate; the institutions and academic centres of medical excellence with whom we have partnered in our work; and finally to the patients whom we serve. South Africa has and continues to participate in many key AstraZeneca projects over all therapeutic areas and is experienced in conducting phase I-IV trials. Currently, AstraZeneca SA is involved in 10 trials spanning many therapeutic areas and is working with over 120 clinical centres, offering new developments to approximately 1300 patients throughout the country.  We also conduct Contract Research Organisation (CRO) led studies locally.

Global research studies in our country include:

  • DISCOVER: A global real world evidence study of patients with type 2 diabetes mellitus that is moving the frontiers of Medicine.
  • COPVAR: A cross-sectional study of patients with severe COPD to assess patient perception of symptom variability in Middle East & Africa countries.

Externally sponsored scientific research studies in South Africa include:

  • A prospective, longitudinal, epidemiological study to categorise and electronically capture data of all respiratory patients attending the outpatients clinic at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in South Africa.

    The study will aim to electronically capture data as well as attempt to standardise the clinical assessment and therapeutic interventions on all patients attending the various pulmonology outpatient clinics at the CMJAH. The study will also introduce various tools validated for assessment of the different pulmonary disease entities and use these objective scoring systems to assess patient severity and response to therapy.
  • Lung function predictive equations for healthy South African children and adults: The Paediatric and Adult African Spirometry Working Group. This study will aim to determine the normal reference equations for spirometry in South African adults and children.


The AstraZeneca Research Trust

In 2014 AstraZeneca South Africa launched the Research Trust. The not-for-profit grant fund, independently managed by a scientific steering committee, supports local academic medical research funding in the area of non-communicable diseases, including cardiovascular/ metabolic diseases and cancer.

Through the academic research grants, conferred for high level studies, including doctoral and post-doctoral work, we hope to generate much needed accurate data in the area of non-communicable diseases. Through the Research Trust we aim to make a positive contribution to science in South Africa by stimulating local research and strengthening the medical research capability.

Go to website


Unlocking the power of what science can do.

We market medicines that are designed to improve the health and quality of life of patients, focusing on 3 main therapy areas: Respiratory; Cardiovascular and Metabolic diseases (CVMD) with newer treatments in Type 2 Diabetes Mellitus being our core strength; and Oncology with targeted and immune-oncology therapies being the future portfolio in cancer management.


AstraZeneca has a patient-centric approach to disease treatment, so we are tackling multiple risk factors by uniting our cardiovascular (CV), metabolic and chronic kidney disease (CKD) disease areas into one integrated approach – cardiovascular and metabolic disease (CVMD). This approach means we look at the CVMD patient as a whole, rather than by disease area, because we know that cardiovascular disease (CVD) is a well-known consequence of diabetes and CKD.

Diabetes is a disease of epidemic scale and an important strategic focus for AstraZeneca. With reportedly nearly 2 million people1 living with diabetes in South Africa, we are focused on redefining the Type 2 diabetes treatment approach and harnessing complementary mechanisms of action, as well as harnessing cardiovascular outcomes benefits.

As we aim to break through conventional thinking by following what science is telling us, we will continue to support patients, physicians and healthcare systems to address the South African burden of CVMD.


For more than 40 years we have developed drugs to combat cancer, many of which have increased survival rates for patients around the world. We aim to advance the science of oncology with a combination-focused pipeline set to address the unmet clinical needs in a host of cancers. Our vision is to redefine the cancer treatment paradigm in South Africa.

In South Africa AstraZeneca has a proven track record of working collaboratively and successfully with the Government and health partners to bring medicines for chronic conditions to South African patients in a timely manner and securing expanded access to these medicines via our Phakamisa programme.


Our goal is to establish a leading position in Asthma and Chronic Obstructive Pulmonary Disease (COPD). We aim to bring value to the broader scientific community in South Africa, held redefine standards of care and raise awareness of the ongoing unmet medical need in Asthma and COPD.

AstraZeneca South Africa will continue to optimise clinical practice through a range of differentiated inhaled therapies, novel combinations and devices for asthma and COPD to improve choice and outcomes for patients. Our inhaled treatments are the foundation of our respiratory portfolio in South Africa and core to our business.


  • We have a strong scientific team of qualified Medical Doctors and Specialists providing key scientific support, across our key Therapeutic Areas, to our AstraZeneca teams and our customers.
  • We collaborate with different medical societies to increase awareness of global management guidelines. We continually explore additional areas for collaboration with medical and pharma societies, with the aim of supporting the education of Health Care Professionals (HCPs).  
  • We have worked extensively to bring some of the best educational resources and key experts to South Africa to expand scientific education programmes and knowledge sharing amongst HCPs.
  • AstraZeneca South Africa utilises live WebEx platforms to host international speakers, bringing international knowledge to the region and combining this with local expertise to promote knowledge sharing.
  • The ePD platform in South Africa, provides doctors access to current, relevant content with international and local speakers. An interactive learning experience utilising technology that offers a solution that best suits doctors’ needs and time.
  • MyWallet is a CPD management solution. It assists practitioners in keeping track of their CPD points and simplifies access to certificates. MyWallet stores all CPD points collected locally and internationally providing an auditable record of their continuing professional education.


At AstraZeneca we work together across global boundaries to make an impact and find answers to challenges.

In South Africa we consider our responsibility to our patients and our community as an integral part of what we do. When we see an opportunity for change we seize it and make it happen, because an opportunity no matter how small can be the start of something big.

Our commitment to improve health outcomes for South African patients extends far beyond our medicines. We offer programmes that advance patient health and access along the care continuum and provide reliable support networks.  

Phakamisa Oncology

Our Phakamisa Oncology programme in South Africa brings together different organisations to help raise awareness of breast & prostate cancer; strengthen healthcare capabilities; and improve access to treatment and support networks.

The vision of the program is to reduce the burden of breast & prostate cancer a on the national health system by the promotion of primary prevention, early detection and access to affordable medicines.

In collaboration with South Africa’s Phakamisa Partners, we are providing accredited courses in cancer diagnosis, treatment and care to doctors, nurses and other healthcare professionals. And in partnership with the Cancer Association of South Africa and the Breast Health Foundation, we are training teams of volunteers and counsellors to go out into the community, raising awareness and supporting patients, as Phakamisa ‘Navigators’.

Phakamisa Healthy Lung

Chronic respiratory diseases represent a challenge to public health in South Africa because of their frequency, severity, projected trends, and economic impact.

With our strong presence in oncology and respiratory therapy areas in Africa, AstraZeneca is committed to improving the lungs of all the women, men and children in South Africa

In 2017 AstraZeneca South Africa embarked on our innovative Phakamisa Healthy Lung programme to address the challenges of lung disease in our country. The programme expands on the current successful model of Phakamisa Oncology, with a focus on supporting raising awareness, promoting  early detection and diagnosis and increasing access to reduce the burden of Asthma, COPD and Lung Cancer.


A healthier world begins with education to help individuals make informed decisions and navigate available tools and resources.

Our Yes2Life Diabetes Patient Support Programme in South Africa, in partnership with Health Window, offers patients telephonic support on disease education and adherence to medication. The programme also offers face-to-face patient support on prescribed medication and disease management provided by diabetes case managers.


At AstraZeneca South Africa we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. By truly following the science, we pioneer new methods, new thinking and bring unexpected teams together.

From medical science to sales & marketing, we’re on a mission to turn ideas into life-changing medicines that transform lives.

If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.


Good governance is crucial to ensuring we are well managed and can deliver our strategic priorities. Our Code of Conduct sets out the ethical standards we expect of everyone who works at AstraZeneca and, along with our global policies, how these are to be translated into consistent actions worldwide.


The safety of patients who take our medicines is of fundamental importance to AstraZeneca. We continuously work to identify and minimise the risks and maximise the benefits of each of our medicines. A vital aspect of our commitment to patient safety is making sure that accurate up-to-date information is provided to support effective use of our medicines.

If you would like to report an adverse event for an AstraZeneca product, please contact AstraZeneca Safety:

Phone: +27 11 797 6193
Mobile: +27 72 758 7638
Fax: +27 11 797 6019

Digital AE reporting is now available using the link: